CN113509559A - CO and drug release synergistic therapeutic agent and preparation method and application thereof - Google Patents
CO and drug release synergistic therapeutic agent and preparation method and application thereof Download PDFInfo
- Publication number
- CN113509559A CN113509559A CN202110345459.5A CN202110345459A CN113509559A CN 113509559 A CN113509559 A CN 113509559A CN 202110345459 A CN202110345459 A CN 202110345459A CN 113509559 A CN113509559 A CN 113509559A
- Authority
- CN
- China
- Prior art keywords
- uio
- tpp
- therapeutic agent
- metal
- synergistic therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 63
- 230000002195 synergetic effect Effects 0.000 title claims abstract description 34
- 229940079593 drug Drugs 0.000 title claims abstract description 32
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000002105 nanoparticle Substances 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 239000011148 porous material Substances 0.000 claims abstract description 12
- 239000012621 metal-organic framework Substances 0.000 claims abstract description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 28
- 229960003160 hyaluronic acid Drugs 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 23
- 239000008055 phosphate buffer solution Substances 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 20
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000010992 reflux Methods 0.000 claims description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- YYGZWQNDFRCZIF-UHFFFAOYSA-N 2,5-bis(sulfanyl)terephthalic acid Chemical compound OC(=O)C1=CC(S)=C(C(O)=O)C=C1S YYGZWQNDFRCZIF-UHFFFAOYSA-N 0.000 claims description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 238000004729 solvothermal method Methods 0.000 claims description 5
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- 239000002114 nanocomposite Substances 0.000 claims description 4
- -1 polytetrafluoroethylene Polymers 0.000 claims description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 claims description 3
- NGRZMGCGHOSCBJ-UHFFFAOYSA-N OC(CCCCC(C=CC=C1)=C1P(C1=CC=CC=C1)C1=CC=CC=C1)=O.Br Chemical compound OC(CCCCC(C=CC=C1)=C1P(C1=CC=CC=C1)C1=CC=CC=C1)=O.Br NGRZMGCGHOSCBJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000005057 refrigeration Methods 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 24
- 238000002512 chemotherapy Methods 0.000 abstract description 14
- 239000002253 acid Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 29
- 239000000243 solution Substances 0.000 description 25
- 239000000463 material Substances 0.000 description 20
- 230000008685 targeting Effects 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000007789 gas Substances 0.000 description 16
- 210000003470 mitochondria Anatomy 0.000 description 12
- 238000012377 drug delivery Methods 0.000 description 11
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 230000002438 mitochondrial effect Effects 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 8
- 229940043267 rhodamine b Drugs 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 7
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000000862 absorption spectrum Methods 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- NFNXWBARWMNOCJ-UHFFFAOYSA-N CNS(OC(C(C=C1)=CC=C1C(O)=O)=O)(=O)=S Chemical compound CNS(OC(C(C=C1)=CC=C1C(O)=O)=O)(=O)=S NFNXWBARWMNOCJ-UHFFFAOYSA-N 0.000 description 4
- LPODFTOMTDVTOE-UHFFFAOYSA-N CSNCOOC(C(C=C1)=CC=C1C(O)=O)=O Chemical compound CSNCOOC(C(C=C1)=CC=C1C(O)=O)=O LPODFTOMTDVTOE-UHFFFAOYSA-N 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000001132 ultrasonic dispersion Methods 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- UQOUOXLHXPHDHF-UHFFFAOYSA-N diethyl 2,5-dihydroxybenzene-1,4-dicarboxylate Chemical compound CCOC(=O)C1=CC(O)=C(C(=O)OCC)C=C1O UQOUOXLHXPHDHF-UHFFFAOYSA-N 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- TUEBLFLFUPIFCM-UHFFFAOYSA-N CSC(N)OOC(C(C=C1)=CC=C1C(O)=O)=O Chemical compound CSC(N)OOC(C(C=C1)=CC=C1C(O)=O)=O TUEBLFLFUPIFCM-UHFFFAOYSA-N 0.000 description 2
- SNSOZEGJUOLTQE-UHFFFAOYSA-N CSNCS(OC(C(C=C1)=CC=C1C(O)=O)=O)(=O)=O Chemical compound CSNCS(OC(C(C=C1)=CC=C1C(O)=O)=O)(=O)=O SNSOZEGJUOLTQE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 229910007932 ZrCl4 Inorganic materials 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940045348 brown mixture Drugs 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012973 diazabicyclooctane Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 239000013110 organic ligand Substances 0.000 description 2
- YLLIGHVCTUPGEH-UHFFFAOYSA-M potassium;ethanol;hydroxide Chemical compound [OH-].[K+].CCO YLLIGHVCTUPGEH-UHFFFAOYSA-M 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 238000000584 ultraviolet--visible--near infrared spectrum Methods 0.000 description 2
- MLOSJPZSZWUDSK-UHFFFAOYSA-N 4-carboxybutyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(CCCCC(=O)O)C1=CC=CC=C1 MLOSJPZSZWUDSK-UHFFFAOYSA-N 0.000 description 1
- 108010003320 Carboxyhemoglobin Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229910007926 ZrCl Inorganic materials 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 230000007946 glucose deprivation Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000013105 nano metal-organic framework Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 238000007626 photothermal therapy Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- VSZWPYCFIRKVQL-UHFFFAOYSA-N selanylidenegallium;selenium Chemical compound [Se].[Se]=[Ga].[Se]=[Ga] VSZWPYCFIRKVQL-UHFFFAOYSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/008—Supramolecular polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a CO and drug release synergistic therapeutic agent, and a preparation method and application thereof, and belongs to the technical field of medicines. The synergistic therapeutic agent comprises metal-organic skeleton nanoparticles Uio-66-SH-TPP and hyaluronic acidThe acid is used as a shell to wrap the outer surface of the metal-organic framework nano-particles Uio-66-SH-TPP; the skeleton of the metal-organic skeleton nanoparticle Uio-66-SH-TPP is modified with Fe through a coordination bond3(CO)12The drug 5-FU is adsorbed in the pore canal of the metal-organic framework nano-particle Uio-66-SH-TPP. The synergistic therapeutic agent of the invention can realize the synergistic treatment of CO gas treatment and chemotherapy, not only improve the accuracy of treating focal areas, but also enhance the treatment effect.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a mitochondrion-targeted CO and drug release synergistic therapeutic agent, and a preparation method and application thereof.
Background
Cancer is one of the most serious public health problems in the world, and direct therapies such as chemotherapy, photodynamic therapy and photothermal therapy have been widely used for cancer treatment. However, these therapies all face a common problem in that they have limited killing power against cancer cells and have toxic side effects against normal cells. These drawbacks severely hamper the effective use of these therapies in the treatment of cancer. Although CO is a toxic gas, more and more studies show that the endogenous gas generated by heme metabolism is an important physiological gas signal molecule, plays an indispensable role in cytoprotection and maintaining intracellular environmental balance, and can effectively regulate various signal pathways in cells, especially processes related to apoptosis and inflammatory reaction. However, CO and hemoglobin are very easily combined, which causes various problems such as dose control, targeted delivery, etc. when CO is used as an inhaled medicament. Therefore, the establishment of a targeted drug delivery system and the controlled release are the key points for improving the treatment effect of the CO gas.
Chemotherapy remains one of the most important methods for cancer treatment. However, Tumor Microenvironments (TMEs) are often characterized by hypoxia, high hydrogen peroxide concentrations, glucose deprivation and low pH, which directly affect the chemotherapeutic effect of cancer to a large extent. The chemotherapy mode of a single anti-tumor drug may induce solid tumors to generate drug resistance and immunosuppressive effects, while the multiple chemotherapy mode of combining multiple anti-tumor drugs shows that chemotherapy is remarkably enhanced. Research shows that gas therapy is an emerging new tumor therapy strategy with great application prospect, and the synergistic chemotherapy can obviously enhance the effect of cancer therapy. Therefore, it is crucial to design and construct a drug delivery system with good biocompatibility, targeted delivery and controlled release.
Therefore, a drug delivery system targeting tumor cells is constructed, and the characteristics of TME are utilized to stimulate the response of CO gas and the controllable release of drugs, so that the effect of gas therapy and chemotherapy in coordination is realized to improve the tumor treatment effect, and the method has obvious significance.
Disclosure of Invention
It is an object of the present invention to provide a CO and drug release synergistic therapeutic agent for TME response.
Another object of the present invention is to provide a preparation method and application of the above-mentioned synergistic therapeutic agent.
In order to achieve the purpose, the invention adopts the following technical scheme:
a CO and drug release synergistic therapeutic agent comprises metal-organic skeleton nanoparticles Uio-66-SH-TPP and hyaluronic acid, wherein the hyaluronic acid is coated on the outer surface of the metal-organic skeleton nanoparticles Uio-66-SH-TPP as a shell;
the skeleton of the metal-organic skeleton nanoparticle Uio-66-SH-TPP is modified with Fe through a coordination bond3(CO)12The drug 5-FU is adsorbed in the pore canal of the metal-organic framework nano-particle Uio-66-SH-TPP.
The preparation method of the CO and drug release synergistic therapeutic agent comprises the following steps:
step 3, modifying Fe3(CO)12Dispersing Uio-66-SH-TPP in water, adding 5-FU, and stirring to obtain 5-FU adsorbed nano composite particles;
and 4, dispersing the 5-FU adsorbed nano composite particles in water, adding a PBS (phosphate buffer solution) of hyaluronic acid, refrigerating the mixture in a refrigerator, taking out, and centrifuging to obtain the TME-responsive CO and drug release synergistic therapeutic agent.
Further, the solvent thermal method adopted in the step 1 is to place the mixture in a polytetrafluoroethylene high-pressure reaction kettle for reaction for 24 hours at 120 ℃.
Further, the reflux reaction in step 2 was carried out by heating at 70 ℃ and condensing under reflux for 1 hour.
Further, the stirring conditions in the step 3 are 20-30 ℃ and 12 h.
Further, the refrigeration condition in step 4 was 4 ℃ for 2 hours.
The synergistic therapeutic agent prepared by the preparation method comprises Uio-66-SH-TPP nanoparticles with square structures and Fe modified in skeleton3(CO)12The material pore canal adsorbs 5-FU and the surface coating HA for improving the biocompatibility of the material.
The application of the synergistic therapeutic agent in preparing tumor treatment medicines.
Has the advantages that: the invention is realized by reacting H2DMBD is used as an organic ligand of a metal-organic framework (MOFs) material, zirconium (Zr) is used as a metal source, a terminal hydroxyl (-OH) group of the Zr can be coordinated with a carboxyl (-COOH) group on the ligand, and a mitochondrion targeting molecule TPP is introduced while the MOFs are synthesized; the organic ligand with mercapto (-SH) can react with Fe3(CO)12Introducing a CO prodrug through a coordination bond S-Fe, and adsorbing 5-FU in the pore channel of the porous nano MOFs composite material; HA is coated on the surface of the material to construct the synergistic therapeutic agent with controllable CO and a drug release system. The therapeutic agent has the characteristics of targeted transportation and controllable release, and realizes the synergistic treatment of gas therapy and chemotherapy through TME stimulation response control. The invention adopts a step-by-step delivery mode of targeting tumor cell surface and organelles, and designs a drug delivery system capable of releasing CO and 5-FU by TME stimulation, thereby overcoming the defect of gas and drug leakage in the traditional treatment and enhancing the tumor treatment effect. In addition, the synthetic steps of the therapeutic agent are simpler, and the yield is higher; furthermore, the synthesis method is simple and low in cost, so that the method is suitable for large-scale production.
Drawings
FIG. 1 is an SEM photograph (a), Zeta potential (b), UV-vis-NIR spectrum (c) and IR spectrum (d) of Uio-66-SH-TPP nanoparticles of example 1.
FIG. 2 shows Uio-66-SH-TPP @ Fe of example 13(CO)12At 30 mu M H2O2And under the environment of PBS solution (namely 30 mu M. OH) of ferrous sulfate heptahydrate, utilizing an ultraviolet spectrum time change curve (a) of a bovine hemoglobin reduction method and statistics (b) of CO release amount of the bovine hemoglobin reduction method under the environment of PBS solution with different concentrations of OH.
FIG. 3 shows UV spectra (a) of 5-FU at different concentrations in example 1 and standard curves (R) of 5-FU fitted according to the (a) plots2=0.9967) (b)。
FIG. 4 is a graph showing the UV absorption spectrum (a) of Uio-66-SH-TPP of example 1 in water loaded with 5-FU at different time intervals under stirring at room temperature and a time-varying drug loading curve (b) calculated from the graph (a).
FIG. 5 is a graph showing the measurement of 5-FU release in different pH environments of Uio-66-SH-TPP @5-FU of example 1.
FIG. 6 is a photograph showing fluorescence of drug and mitochondrial after mitochondrial staining in example 1, wherein Uio-66-SH and Uio-66-SH-TPP (adsorbing rhodamine B which can generate red fluorescence) were cultured with HeLa cells.
FIG. 7 shows Uio-66-SH-TPP, Uio-66-SH-TPP @ Fe at different concentrations in example 13(CO)12、Uio-66-SH-TPP@ Fe3(CO)12@5-FU、Uio-66-SH-TPP@ Fe3(CO)12The cellular activities of @5-FU @ HA and 5-FU.
Detailed Description
In order to explain the structural features and technical means of the present invention in detail and to achieve the object and effect thereof, the following detailed description is given with reference to the accompanying drawings in combination with the embodiments.
The invention provides a CO and drug release synergistic therapeutic agent with tumor microenvironment response, which comprises Uio-66-SH-TPP nano particles with mitochondrial targeting and Fe modified in a skeleton3(CO)12Uio-66-SH-TPP nano-particle is absorbed with 5-FU in the pore channel, and at the same time, the surface of Uio-66-SH-TPP nano-particle is coated with Hyaluronic Acid (HA) to further enhance the targeting of the drug delivery systemAnd (4) sex.
Specifically, the Uio-66-SH-TPP nanoparticles are square structures with a diameter of about 20 nm.
Ligand 2, 5-dimercaptoterephthalic acid (H) used in the present invention2DMBD), which can be prepared by the following procedure, or a commercially available product can be purchased directly.
2, 5-dimercaptoterephthalic acid (H)2DMBD), comprising the following steps:
(1) synthesis of diethyl 2, 5-bis (methylthioaminomethoxy) terephthalate
Dissolving 5g of diethyl 2, 5-dihydroxyterephthalate and 9g of triethylene Diamine (DABCO) in 50mL of N, N-Dimethylacetamide (DMA), and cooling to 0 ℃ in an ice bath; 9.5g of N, N-dimethylthiocarbonyl chloride was dissolved in 25mL of DMA, and the mixture was dissolved completely with sonication and then placed in nitrogen (N)2) Slowly dripping the solution into the solution in the previous step by using a constant-pressure dropping funnel under protection, and keeping the temperature at 0 ℃; after the dropwise addition is completed, the mixed solution is stirred for 16 hours at room temperature to generate white precipitate, and the white precipitate is filtered, washed by a large amount of water and dried in a vacuum strip to obtain the compound diethyl 2, 5-bis (methylthio-amino-methoxy) terephthalate.
(2) Synthesis of diethyl 2, 5-bis (methylthiosulfamoyl) terephthalate
In N2Under protection, the synthesized diethyl 2, 5-bis (methylthioaminomethoxy) terephthalate is heated and stirred at 230 ℃ for 1h, the obtained brown mixture is slowly cooled to 70 ℃, 20mL of ethanol is added into the mixture by a constant pressure dropping funnel, the mixture is slowly cooled to room temperature to obtain light brown crystals, the light brown crystals are filtered and dried, and finally the compounds are purified by a column to obtain the diethyl 2, 5-bis (methylthioaminomethylsulfonyl) terephthalate.
(3) Synthesis of 2, 5-dimercaptoterephthalic acid
Preparation of 1.3 mol. L-1KOH ethanol/water (1:1) solution, and 20mL is degassed for 1 h; the diethyl 2, 5-bis (methylthiosulfamoyl) terephthalate obtained by the reaction was dissolved in a degassed KOH ethanol/water (1:1) solution in N2Refluxing for 3h at 85 ℃ under protection; the reaction mixture was cooled to room temperatureThen 10mL of concentrated hydrochloric acid is added in an ice bath to generate bright yellow precipitate, and the precipitate is filtered, washed by a large amount of water and dried in vacuum to obtain ligand 2, 5-dimercapto terephthalic acid (H)2DMBD）。
The preparation method of the synergistic therapeutic agent comprises the following steps:
9.6mg of zirconium tetrachloride (ZrCl)4) 9.5mg of H2DMBD, 5mg of (4-carboxybutyl) triphenyl phosphonium bromide (TPP) and 750 muL of glacial acetic acid are added into 10mL of N, N-Dimethylformamide (DMF), and the mixture is subjected to ultrasonic dispersion and then transferred into a polytetrafluoroethylene high-pressure reaction kettle for reaction at 120 ℃ for 24 hours. After the reaction is finished and cooled to room temperature, the mixture is centrifugally washed by DMF for 3 times, then is centrifugally washed by absolute ethyl alcohol for 3 times, and is dried in vacuum to obtain Uio-66-SH-TPP.
The process for preparing Uio-66-SH is similar to the process for preparing Uio-66-SH-TPP, and only the raw material TPP is removed.
The optimal temperature for the reaction is 120 ℃ and the reaction time is 24 h. The obtained Uio-66-SH-TPP nanoparticles have a diameter of about 20 nm.
25mg of Uio-66-SH-TPP, 50 mg of Fe3(CO)12And 50mL of tetrahydrofuran were added to the round-bottom flask, and after ultrasonic dispersion, the mixture was heated at 70 ℃ to condense and reflux for 1 h. Finally, the product was collected by centrifugation, washed 3 times with anhydrous ethanol and dried in vacuo to yield Uio-66-SH-TPP @ Fe3(CO)12。
The 2, 5-dihydroxy-terephthalic acid diethyl ester, triethylene diamine, N, N-dimethyl thiocarbonyl chloride and ZrCl4KOH, DMA and DMF are all commonly used chemical raw materials and 5-FU and HA for the next step, and can be directly ordered from the reagent network.
Step 3, adsorbing 5-FU to Uio-66-SH-TPP @ Fe by adopting a normal-temperature stirring method3(CO)12Inside the nanometer particle pore canal;
5.5mg of Uio-66-SH-TPP @ Fe3(CO)12Is dispersed in 10mL of PBS was added 14mg of 5-FU and magnetically stirred at room temperature overnight, collected by centrifugation and washed 3 times with water to give Uio-66-SH-TPP @ Fe3(CO)12@5-FU。
Preparation of Uio-66-SH-TPP @5-FU was performed as described for Uio-66-SH-TPP @ Fe3(CO)12The process of @5-FU is similar, except that Uio-66-SH-TPP @ Fe raw material is used3(CO)12The replacement is Uio-66-SH-TPP.
The method for preparing Uio-66-SH and Uio-66-SH-TPP adsorbing Rhodamine B (RB) capable of generating red fluorescence is similar to the method for preparing Uio-66-SH-TPP @5-FU, and only the raw material 5-FU is changed into RB.
15mg of Uio-66-SH-TPP @ Fe3(CO)12@5-FU was dispersed in 4mL of water, and 15mg of Hyaluronic Acid (HA) (dissolved in 6mL of PBS solution) was gradually added. Refrigerating the mixture in a refrigerator at 4 deg.C for 2h, centrifuging, collecting and washing with water for 2 times to obtain Uio-66-SH-TPP @ Fe3(CO)12@5-FU@HA。
The synergistic therapeutic agent prepared by the preparation method comprises Uio-66-SH-TPP nanoparticles with square structures and Fe modified in skeleton3(CO)12The material pore canal adsorbs 5-FU and the surface coating HA for improving the biocompatibility of the material.
The Uio-66-SH-TPP nano-particles are about 20nm in diameter and Fe is introduced into the skeleton3(CO)12And 5-FU is adsorbed by the pore channel and HA is coated on the surface of the pore channel for functional modification.
The synergistic therapeutic agent has the synergistic therapeutic function of CO gas treatment and chemotherapy, and is Uio-66-SH-TPP @ Fe3(CO)12Has mitochondria targeting and mitochondria internal OH can trigger the release of CO. The co-therapeutic agent nanomaterial comprises 5-FU which can stimulate release in response to chemotherapy using the low pH in TME. HA coated on the surface of the material can achieve the purpose of tumor-targeted drug delivery with a receptor overexpressed on the surface of a tumor cell through a ligand-receptor binding mechanism, and TPP targets the inside of mitochondria of the tumor cell. Thus, cell targeting andthe gradual targeting effect of organelle (mitochondria) targeting enhances the targeting of the synergistic therapeutic agent. Therefore, the constructed drug delivery system can realize the synergistic treatment of CO gas treatment and chemotherapy, thereby not only improving the accuracy of treating the focal region, but also enhancing the treatment effect.
The synergistic therapeutic agent prepared by the method can be applied as a preparation for treating tumors.
The preparation for treating the tumor is gas therapy synergistic chemotherapy of the synergistic therapeutic agent under the condition that the stimulation responds to CO gas and drug release.
It is understood that the synergistic treatment can inhibit the growth of tumor cells and kill cancer cells, and therefore, the synergistic therapeutic agent of the present invention is a highly effective, low-toxicity, green tumor treatment.
The preparation method of the tumor synergistic therapeutic agent has the advantages of low price of synthetic raw materials, simple preparation process and easy large-scale production. In addition, the synergistic therapeutic agent prepared by the preparation method has good monodispersity and stability, good biocompatibility, high tumor targeting property and controllable CO and 5-FU release.
The present invention will be further illustrated by the following specific examples.
Example 1
(1) Preparation of ligand H2DMBD
A. Synthesis of diethyl 2, 5-bis (methylthioaminomethoxy) terephthalate
Dissolving 5g of diethyl 2, 5-dihydroxyterephthalate and 9g of DABCO in 50mL of DMA, and cooling to 0 ℃ in an ice bath; 9.5g of N, N-dimethylthiocarbonyl chloride was dissolved in 25mL of DMA, and after complete dissolution by sonication, the mixture was dissolved in N2Slowly dripping the solution into the solution in the previous step by using a constant-pressure dropping funnel under protection, and keeping the temperature at 0 ℃; after the dropwise addition is completed, the mixed solution is stirred for 16 hours at room temperature to generate white precipitate, and the white precipitate is filtered, washed by a large amount of water and dried in a vacuum strip to obtain the compound diethyl 2, 5-bis (methylthio-amino-methoxy) terephthalate.
B. Synthesis of diethyl 2, 5-bis (methylthiosulfamoyl) terephthalate
In N2Under protection, the synthesized diethyl 2, 5-bis (methylthioaminomethoxy) terephthalate is heated and stirred at 230 ℃ for 1h, the obtained brown mixture is slowly cooled to 70 ℃, 20mL of ethanol is added into the mixture by a constant pressure dropping funnel, the mixture is slowly cooled to room temperature to obtain light brown crystals, the light brown crystals are filtered and dried, and finally the compounds are purified by a column to obtain the diethyl 2, 5-bis (methylthioaminomethylsulfonyl) terephthalate.
C. Synthesis of 2, 5-dimercaptoterephthalic acid
Preparation of 1.3 mol. L-1KOH ethanol/water (1:1) solution, and 20mL is degassed for 1 h; the diethyl 2, 5-bis (methylthiosulfamoyl) terephthalate obtained by the reaction was dissolved in a degassed KOH ethanol/water (1:1) solution in N2Refluxing for 3h at 85 ℃ under protection; after the reaction mixture is cooled to room temperature, 10mL of concentrated hydrochloric acid is added in an ice bath to generate bright yellow precipitate, and the precipitate is subjected to suction filtration, washing with a large amount of water and vacuum drying to obtain the compound 2, 5-dimercapto terephthalic acid.
(2) Uio-66-SH-TPP nanoparticles;
9.6mg of ZrCl49.5mg of H2DMBD, 5mg TPP and 750 mu L glacial acetic acid are added into 10mLDMF, and the mixture is transferred into a polytetrafluoroethylene high-pressure reaction kettle for reaction at 120 ℃ for 24 hours after ultrasonic dispersion. After the reaction is finished and cooled to room temperature, the mixture is centrifugally washed by DMF for 3 times, then is centrifugally washed by absolute ethyl alcohol for 3 times, and is dried in vacuum to obtain Uio-66-SH-TPP.
The process for preparing Uio-66-SH is similar to the process for preparing Uio-66-SH-TPP, and only the raw material TPP is removed.
(3) Preparation Uio-66-SH-TPP @ Fe3(CO)12;
25mg of Uio-66-SH-TPP, 50 mg of Fe3(CO)12And 50mL of THF were added to the round-bottom flask, and after ultrasonic dispersion, the mixture was heated at 70 ℃ to condense at reflux for 1 h. Finally, the product was collected by centrifugation, washed 3 times with anhydrous ethanol and dried in vacuo to yield Uio-66-SH-TPP @ Fe3(CO)12。
(4) Preparation Uio-66-SH-TPP @ Fe3(CO)12@5-FU;
5.5mg of Uio-66-SH-TPP @ Fe3(CO)12Dispersing in 10mL PBS, adding 14mg 5-FU, magnetically stirring at room temperature overnight, centrifuging, collecting, and washing with water for 3 times to obtain Uio-66-SH-TPP @ Fe3(CO)12@5-FU。
Preparation of Uio-66-SH-TPP @5-FU was performed as described for Uio-66-SH-TPP @ Fe3(CO)12The process of @5-FU is similar, except that Uio-66-SH-TPP @ Fe raw material is used3(CO)12The replacement is Uio-66-SH-TPP.
The method for preparing Uio-66-SH and Uio-66-SH-TPP adsorbing Rhodamine B (RB) capable of generating red fluorescence is similar to the method for preparing Uio-66-SH-TPP @5-FU, and only the raw material 5-FU is changed into RB.
(5) Preparation Uio-66-SH-TPP @ Fe3(CO)12@5-FU@HA;
15mg of Uio-66-SH-TPP @ Fe3(CO)12@5-FU was dispersed in 4mL of water, and 15mg of HA (dissolved in 6mL of PBS solution) was gradually added. Refrigerating the mixture in a refrigerator for 2h, centrifuging, collecting and washing with water for 2 times to obtain Uio-66-SH-TPP @ Fe3(CO)12@5-FU@HA。
And (3) performance testing:
1. Uio-66-SH-TPP nanoparticle morphology determination
FIG. 1 is SEM (a), Zeta potential (b), infrared spectrum (c) and ultraviolet-visible-near infrared spectrum (d) of Uio-66-SH-TPP nanoparticles prepared in example 1. As a result, it was found that the synthesized Uio-66-SH-TPP nanoparticles have a diameter of about 20nm in graph (a). FIG. (b) shows Uio-66-SH-TPP @ Fe prepared3(CO)12The Zeta potential of the material is larger than that of Uio-66-SH-TPP nano-particles, and the absolute value of the potential value of the Zeta potential is larger, so that the stability of the material is better. As can be seen from the graph (c), the prepared Uio-66-SH-TPP nanoparticles have good light absorption in the vacuum ultraviolet region. FIG. (d) shows Uio-66-SH-TPP @ Fe prepared3(CO)12Both Uio-66-SH-TPP and Fe3(CO)12Characteristic peak of (2).
2. Determination of Uio-66-SH-TPP @ Fe3(CO)12CO evolution in an OH Environment
The release of CO is indirectly detected by spectrophotometry through the conversion of an ultraviolet absorption peak from 430nm (an absorption peak of Hb) to 410nm (an absorption peak of HbCO) in the process of carbonyl hemoglobin (HbCO) after the combination of bovine hemoglobin (Hb) and CO.
First, Uio-66-SH-TPP @ Fe prepared in example 13(CO)12Preparing a PBS solution with the concentration of 100 mug/mL, dissolving freshly prepared Hb (4.2 muM) in the PBS solution (pH =7.4), adding 1.2mg of sodium dithionite for reducing the Hb solution, adding 75 muL of a prepared material with the concentration, and then adding the prepared material into a solution (30 muM, 10 muM, 0 mug M H) with different concentrations of OH2O2And ferrous sulfate heptahydrate in PBS, pH = 7.4). The entire reaction solution (3mL) was immediately sealed in a 4mL ultraviolet quartz tube. Ultraviolet absorption spectrum of solution: (I= 350-600 nm) were collected on a uv/vis spectrophotometer. To eliminate influencing factors and to improve accuracy, due to HbCO and Hb, respectivelyITwo strong absorbing bands of = 410 and 430nm were used to quantify the conversion of Hb to HbCO, resulting in fig. 2(a), then by calculation formula
(Cco represents the concentration of CO,I 410nmrepresents HbCO inI= ultraviolet absorbance value at 410nm,I 430nmrepresents Hb inI= ultraviolet absorbance value at 430 nm) to obtain Uio-66-SH-TPP @ Fe3(CO)12CO release profile 2(b) in PBS solution at 30 μ M. OH. From FIG. 2(b), Uio-66-SH-TPP @ Fe3(CO)12The amount of CO released at various concentrations of OH increases with increasing OH concentration.
3. Standard curve for 5-FU
Aqueous solutions of 5-FU at different concentrations were prepared at 0.002mg/mL, 0.004mg/mL, 0.006mg/mL, 0.008mg/mL, 0.010mg/mL, 0.012mg/mL, 0.014mg/mL, 0.016mg/mL, 0.018mg/mL, and 0.020mg/mL, respectively. When the UV absorption spectrum of 5-FU was measured at different concentrations, it can be seen from FIG. 3(a) that 5-FU had a maximum absorption peak at 262nm, and the maximum absorption peak increased with the increase in concentration. At 262nm according to different concentrationsCorresponding UV absorption values were plotted as a standard curve, and it can be seen from FIG. 3(b) that there is a good linear relationship (R)2=0.9967), the concentration (X) as a function of the absorption value (Y) can also be obtained: y = 47.44X-0.003867.
4. Uio-66-SH-TPP @5-FU
5.5mg of Uio-66-SH-TPP @ Fe3(CO)12Dispersed in 10mL of PBS, and added with 14mg of 5-FU and magnetically stirred at room temperature. 3mL of the reaction solution was collected at time intervals of 0.5h, 1.0h, 1.5h, 2.0h, 3.0h, 4.0h, 5.0h, 6.0h, 7.0h, 8.0h, 9.0h, 10h, 11h and 12h, and the supernatant was collected after centrifugation to measure the UV absorption spectrum. As can be seen from FIG. 4(a), the absorbance of the supernatant decreased with the increase of the reaction time, indicating that 5-FU was adsorbed into the pores of the material. According to the standard curve of 5-FU, calculating the 5-FU which is not adsorbed in the supernatant liquid of different reaction time, indirectly calculating the drug loading amount of different time, wherein the change of the loading amount is shown in figure 4(b), and the 5-FU is gradually adsorbed into the material and reaches the stable adsorption along with the extension of the reaction time.
5. Determination of Uio-66-SH-TPP @5-FU drug Release under different pH environments
4mg/mL Uio-66-SH-TPP @5-FU aqueous solution prepared in example 1 was added to 10mL PBS solutions prepared to have pH values of 4.6, 5.5, 6.5 and 7.4, 3mL of the reaction solution was taken at intervals of 2.0h, 4.0h, 6.0h, 8.0h, 10h, 12h and 14h, and the supernatant was centrifuged to measure the UV absorption spectrum. 5-FU released from the supernatant at different reaction times was calculated according to the standard curve of 5-FU, and the release of the drug at different times for each pH was calculated, and the change in the release is shown in FIG. 5, in which it can be seen that the release of 5-FU increases with decreasing pH, indicating that 5-FU is released under acidic conditions.
6. Determination of mitochondrial targeting of Uio-66-SH and Uio-66-SH-TPP
Drug fluorescence and mitochondrial fluorescence pictures after mitochondrial staining in HeLa cell culture
Uio-66-SH and Uio-66-SH-TPP (after RB adsorption) prepared in example 1 were formulated as 320 μ g/mL (pH =7.4) PBS solution, adding 10 portions of HeLa cells5The density of each well was seeded into 2. phi.20 mm glass-bottom cell culture dishes at 5% CO2Incubate at 37 ℃ for 12 h. Removing old culture medium, adding 1.5mL of fresh culture medium, adding 500 μ L of prepared material respectively, and adding 5% CO2Incubate at 37 ℃ for 4 h. The cell dish was washed with PBS to remove non-ingested particles, 1.5mL of fresh medium and 500 μ L of mitochondrial stain were added at 5% CO2Incubate at 37 ℃ for 45 minutes. Washing the cell dish by PBS to remove the non-ingested staining agent, adding 500 muL of 4% paraformaldehyde cell fixing solution, washing the cell dish by PBS to remove the redundant fixing solution after fixing for 20 minutes, and observing the mitochondrial targeting of the cell dish and the cell dish by a fluorescence microscope after adding 1mLPBS respectively. From FIG. 6, it can be seen that the red fluorescence represents the position of the material, and the green fluorescence represents the position of the mitochondria, and from the superimposed fluorescence image of the two, it can be seen that Uio-66-SH is mostly red, and Uio-66-SH-TPP has a lot of yellow colors with the superposition of red and green, which indicates that Uio-66-SH-TPP has stronger targeting property to mitochondria than Uio-66-SH.
7. Materials of different concentrations Uio-66-SH-TPP, Uio-66-SH-TPP @ Fe3(CO)12、Uio-66-SH-TPP@ Fe3(CO)12@5-FU、Uio-66-SH-TPP@ Fe3(CO)12Cellular Activity of @5-FU @ HA and 5-FU
Cell viability of Hela cells was determined by using the thiazole blue (MTT) assay. The cells were treated with 104Cell/well density was seeded into 96-well cell culture plates and at 5% CO2Incubate at 37 ℃ for 12 h. Then, the drug adding medicines are added with Uio-66-SH-TPP and Uio-66-SH-TPP @ Fe of 50 muL per hole3(CO)12、Uio-66-SH-TPP@ Fe3(CO)12@5-FU、Uio-66-SH-TPP@ Fe3(CO)12@5-FU @ HA and 5-FU were dispersed in DMEM, with different concentrations (5, 10, 20, 40, 80 and 160 μ g/mL) added to each well. Cells were incubated at 5% CO2Incubate at 37 ℃ for a further 24 h. After incubation, old media was removed and cell wells were washed with PBS to remove non-ingested particles, then 100 μ L of fresh media was added. Then 10 μ L of filter sterilized MTT reagent (5 mg/mL in PBS) was added to each well and the plates were placed at 37%Incubate at ° C. After a further 4h incubation, the medium was removed and precipitated formazan crystals were dissolved by addition of DMSO. The absorbance of solubilized formazan crystals in each well was measured using a microplate reader at 450 nm. The cell viability at each concentration was calculated by taking the non-drug-treated cells as a control group and recording the cell activity as 100%. All samples were prepared in triplicate.
As can be seen from the cytotoxicity results in FIG. 7, the cell activity of Uio-66-SH-TPP is above 97%, which indicates that the cytotoxicity is low and the biocompatibility of the material is good; Uio-66-SH-TPP @ Fe3(CO)12The cell activity was lower than that of Uio-66-SH-TPP due to the introduced Fe3(CO)12Can target to mitochondria and release CO, and generate gas treatment to reduce the activity of cells; Uio-66-SH-TPP @ Fe3(CO)12@5-FU ratio Uio-66-SH-TPP @ Fe3(CO)12The cell activity of (A) is low because the cell activity is reduced by the release of the material-loaded drug 5-FU under the same conditions under the stimulation of TME, Uio-66-SH-TPP @ Fe3(CO)12The cellular activity of @5-FU is lower than that of 5-FU because of Fe introduced by the material under the same conditions3(CO)12OH in mitochondria can be used to trigger CO release, and gas is generated to treat and reduce cell activity; Uio-66-SH-TPP @ Fe3(CO)12@5-FU @ HA lower than Uio-66-SH-TPP @ Fe3(CO)12Cellular Activity of @5-FU, due to Uio-66-SH-TPP @ Fe3(CO)12HA introduced by @5-FU @ HA can enable the material to be targeted to the surface of cells, the targeting property of a drug delivery system is further enhanced, the toxic and side effects of the drug delivery system on normal cells are reduced, the drug delivery system HAs stronger purpose through a step-by-step targeting mode of cells and mitochondria, cells cannot be killed indiscriminately, and the activity of tumor cells is further reduced.
The synergistic therapeutic agent provided by the invention takes Uio-66-SH-TPP of modified mitochondrion targeting molecule TPP as a carrier and modifies Fe in the framework of the carrier3(CO)12The targeting property of the drug delivery system is further enhanced by adsorbing 5-FU in the pore canal and coating HA on the surface. The first nano MOFs-Uio-66-SH-TPP is prepared by a high-temperature solvothermal method and has a small size of 20 nm. Second pass through the fittingMethod of bonding of Fe3(CO)12Modified into Uio-66-SH-TPP skeleton as precursor for releasing CO gas. Finally, 5-FU and HA are further modified, CO release is triggered by OH in mitochondria, and 5-FU release is stimulated by TME, so that the synergistic treatment effect of CO gas treatment and chemotherapy is finally realized.
Claims (7)
1. A CO and drug release cotherapeutic agent, characterized by: comprises metal-organic skeleton nano-particles Uio-66-SH-TPP and hyaluronic acid, wherein the hyaluronic acid is used as a shell to wrap the outer surface of the metal-organic skeleton nano-particles Uio-66-SH-TPP;
the skeleton of the metal-organic skeleton nanoparticle Uio-66-SH-TPP is modified with Fe through a coordination bond3(CO)12The drug 5-FU is adsorbed in the pore canal of the metal-organic framework nano-particle Uio-66-SH-TPP.
2. The process for the preparation of CO and a drug release cotherapeutic agent of claim 1, wherein: the method comprises the following steps:
step 1, adding 2, 5-dimercaptoterephthalic acid, (4-carboxybutyl) triphenyl phosphine bromide, zirconium tetrachloride and glacial acetic acid into N, N' -dimethylformamide, and synthesizing Uio-66-SH-TPP from the mixture by a solvothermal method;
step 2, adding Fe3(CO)12Uio-66-SH-TPP is added into tetrahydrofuran for reflux reaction to obtain the product modified with Fe3(CO)12Uio-66-SH-TPP of (1);
step 3, modifying Fe3(CO)12Dispersing Uio-66-SH-TPP in water, adding 5-FU, and stirring to obtain 5-FU adsorbed nano composite particles;
and 4, dispersing the 5-FU adsorbed nano composite particles in water, adding a PBS (phosphate buffer solution) of hyaluronic acid, refrigerating the mixture in a refrigerator, taking out, and centrifuging to obtain the TME-responsive CO and drug release synergistic therapeutic agent.
3. The method of claim 2, wherein: in the step 1, the solvothermal method is adopted, and the mixture is placed in a polytetrafluoroethylene high-pressure reaction kettle to react for 24 hours at 120 ℃.
4. The method of claim 2, wherein: the reflux reaction in step 2 is carried out by heating, condensing and refluxing for 1h at 70 ℃.
5. The method of claim 2, wherein: in the step 3, the stirring condition is 20-30 ℃ and 12 h.
6. The method of claim 2, wherein: the refrigeration condition in step 4 is 4 ℃ and 2 h.
7. Use of a cotherapeutic agent according to claim 1 for the manufacture of a medicament for the treatment of tumors.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110345459.5A CN113509559B (en) | 2021-03-31 | 2021-03-31 | CO and drug release synergistic therapeutic agent and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110345459.5A CN113509559B (en) | 2021-03-31 | 2021-03-31 | CO and drug release synergistic therapeutic agent and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113509559A true CN113509559A (en) | 2021-10-19 |
| CN113509559B CN113509559B (en) | 2024-03-15 |
Family
ID=78062053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110345459.5A Active CN113509559B (en) | 2021-03-31 | 2021-03-31 | CO and drug release synergistic therapeutic agent and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113509559B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114479105A (en) * | 2022-01-25 | 2022-05-13 | 福建农林大学 | Metal organic framework material for antibacterial therapy and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106478959A (en) * | 2016-09-23 | 2017-03-08 | 肇庆学院 | A kind of Cd MOF Ji Yu 4,4 ' dicarboxydiphenyl ether and preparation method thereof |
| CN108837159A (en) * | 2018-07-17 | 2018-11-20 | 西北农林科技大学 | A kind of nano antibacterial agent and preparation method thereof |
| CN112121154A (en) * | 2020-10-20 | 2020-12-25 | 南通大学 | Tumor microenvironment response CO gas therapeutic agent and preparation and application thereof |
| CN112210084A (en) * | 2020-10-27 | 2021-01-12 | 洪月恒 | Preparation method of metal organic framework with photocatalytic reduction of carbon dioxide |
| CN113144175A (en) * | 2021-03-31 | 2021-07-23 | 南通大学 | Tumor microenvironment response CO gas therapeutic agent and preparation method and application thereof |
-
2021
- 2021-03-31 CN CN202110345459.5A patent/CN113509559B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106478959A (en) * | 2016-09-23 | 2017-03-08 | 肇庆学院 | A kind of Cd MOF Ji Yu 4,4 ' dicarboxydiphenyl ether and preparation method thereof |
| CN108837159A (en) * | 2018-07-17 | 2018-11-20 | 西北农林科技大学 | A kind of nano antibacterial agent and preparation method thereof |
| CN112121154A (en) * | 2020-10-20 | 2020-12-25 | 南通大学 | Tumor microenvironment response CO gas therapeutic agent and preparation and application thereof |
| CN112210084A (en) * | 2020-10-27 | 2021-01-12 | 洪月恒 | Preparation method of metal organic framework with photocatalytic reduction of carbon dioxide |
| CN113144175A (en) * | 2021-03-31 | 2021-07-23 | 南通大学 | Tumor microenvironment response CO gas therapeutic agent and preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| DANNI JIN ET AL.: "Recent advances in the development of metal– organic framework-based gas-releasing nanoplatforms for synergistic cancer therapy", 《DALTON TRANS.》, vol. 2021, no. 50, 17 December 2020 (2020-12-17), pages 1189 * |
| SONJA PULLEN ET AL.: ""Enhanced Photochemical Hydrogen Production by a Molecular Diiron Catalyst Incorporated into a Metal−Organic Framework"", 《J. AM. CHEM. SOC. 》, vol. 2013, no. 135, pages 16997 * |
| 张兵锋;姜虎林;: "线粒体靶向聚合物TPP-PEI-LND的构建及其特性", 中国药科大学学报, no. 06, pages 659 - 664 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114479105A (en) * | 2022-01-25 | 2022-05-13 | 福建农林大学 | Metal organic framework material for antibacterial therapy and preparation method and application thereof |
| CN114479105B (en) * | 2022-01-25 | 2023-03-14 | 福建农林大学 | Metal organic framework material for antibacterial therapy and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113509559B (en) | 2024-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107412195B (en) | PH-responsive antitumor drug carrier material and preparation and application thereof | |
| Dong et al. | Poly (ethylene glycol) conjugated nano-graphene oxide for photodynamic therapy | |
| Xiao et al. | Multifunctional carbon monoxide nanogenerator as immunogenic cell death drugs with enhanced antitumor immunity and antimetastatic effect | |
| CN112245579B (en) | Photodynamic therapeutic agent for relieving tumor hypoxia and preparation method and application thereof | |
| Gui et al. | A smart copper-phthalocyanine framework nanoparticle for enhancing photodynamic therapy in hypoxic conditions by weakening cells through ATP depletion | |
| Rengaraj et al. | Porous NH2-MIL-125 as an efficient nano-platform for drug delivery, imaging, and ROS therapy utilized low-intensity visible light exposure system | |
| CN108948060B (en) | Triphenylamine branch ligand substituted silicon phthalocyanine and preparation method and application thereof | |
| Arabbaghi et al. | Zn-MOF: an efficient drug delivery platform for the encapsulation and releasing of Imatinib Mesylate | |
| AU2019423049C1 (en) | Copper nanoclusters, thymine-modified hyaluronic acid and poly (copper nanoclusters), method for preparing the same, and application thereof | |
| Mahajan et al. | A potential mediator for photodynamic therapy based on silver nanoparticles functionalized with porphyrin | |
| CN113509559B (en) | CO and drug release synergistic therapeutic agent and preparation method and application thereof | |
| Cui et al. | Metal–organic framework-encapsulated nanoparticles for synergetic chemo/chemodynamic therapy with targeted H 2 O 2 self-supply | |
| CN114790218A (en) | Amorphous MOF nano photosensitizer and preparation method and application thereof | |
| Soltani et al. | Embedding an extraordinary amount of gemifloxacin antibiotic in ZIF-8 framework with one-step synthesis and measurement of its H 2 O 2-sensitive release and potency against infectious bacteria | |
| CN112121154A (en) | Tumor microenvironment response CO gas therapeutic agent and preparation and application thereof | |
| Tan et al. | Near-infrared-responsive nanoplatforms integrating dye-sensitized upconversion and heavy-atom effect for enhanced photodynamic therapy efficacy | |
| Matlou et al. | Effect of symmetry and metal nanoparticles on the photophysicochemical and photodynamic therapy properties of cinnamic acid zinc phthalocyanine | |
| CN113150298A (en) | Covalent organic polymer based on porphyrin and preparation method and application thereof | |
| Luo et al. | Lanthanide-titanium oxo-clusters, new precursors of multifunctional colloids for effective imaging and photodynamic therapy | |
| Shen et al. | Construction of BODIPY functional ZIF-8 with improved visible light-induced antibacterial activity | |
| CN114209825B (en) | Cuprous ion-responsive NO release and photothermal synergistic therapeutic agent and application thereof | |
| CN112058237B (en) | Preparation method of chiral metal organic framework material and application of chiral metal organic framework material in tetracycline hydrochloride sustained release | |
| CN113144175A (en) | Tumor microenvironment response CO gas therapeutic agent and preparation method and application thereof | |
| CN111875623A (en) | Preparation method and application of 5-fluorouracil-1-yl acetic acid bipyridyl copper tetrafluoroborate anticancer functional complex | |
| CN114907381B (en) | Photosensitizer with thiadiazolo [3,4-g ] quinoxaline structure with distorted molecular framework, preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |